Clinical Trials Browser

Phase 2 × OTHER_GOV × brigatinib × Clear all

NCT04074993 2023-09-28

Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung